AusBiotech

Australian antiviral drug development company, Island Pharmaceuticals (ASX:ILA), has signed an agreement to acquire the galidesivir antiviral program from US-based BioCryst Pharmaceuticals.

Regenerative medicine company Orthocell (ASX:OCC) has recorded its first sales revenue from its Remplir nerve repair product in the US.

Race Oncology (ASX:RAC) has secured Human Research Ethics Committee approvals from the Institutional Review Board of The University of Hong Kong to commence its Phase 1 clinical trial of RC220 in combination with doxorubicin at the Prince of Wales and Queen Mary Hospitals.

Imagion Biosystems (ASX:IBX) has updated investors on its planned Phase 2 HER2 breast cancer clinical trial to be conducted in the US.

Neurizon Therapeutics (ASX:NUZ) reports progress across key clinical and regulatory activities for its lead program, NUZ-001, targeting the treatment of amyotrophic lateral sclerosis.

Syntara (ASX:SNT) has announced that the World Health Organization has formally granted the International Non-Proprietary Name of amsulostat to its advanced clinical development asset SNT-5505.

AusBiotech has welcomed 27 new member organisations in the first half of 2025, reinforcing the sector’s growth and momentum.

Neurotech International (ASX: NTI) has announced the publication of its Phase 1/2 clinical trial results for Rett syndrome in the peer-reviewed scientific journal, Journal of Paediatrics and Child Health.

PYC Therapeutics (ASX:PYC) has announced it is progressing the two-part trial of its PYC-003 for Polycystic Kidney Disease.

AusBiotech has announced the 2025 appointments to its state committees, which the organisation describes as a key mechanism for hearing from and engaging with the breadth and diversity of its membership nationwide.

Australian antiviral drug development company Island Pharmaceuticals (ASX:ILA) has announced the appointment of Jason Carroll as its non-executive chairman.

Amplia Therapeutics (ASX:ATX) has announced that an additional confirmed partial response has been recorded in its ongoing ACCENT clinical trial in pancreatic cancer.